HealthDay News — In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Feb. 27 in Practical Radiation Oncology, evidence-based recommendations are ...

Metronomic capecitabine plus AI significantly improved PFS and OS in HR-positive, HER2-negative metastatic breast cancer compared to AI alone. The MECCA trial enrolled 263 patients, with balanced ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

The article by Graetz et al entitled “Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial” (JCO Oncology Practice ...

Sorafenib as a single agent, although well tolerated, does not exhibit significant activity in the treatment of metastatic breast cancer (MBC). Sorafenib, in combination with capecitabine ...

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

This fact is especially pertinent in cancer therapy, where most cytotoxic agents have a steep dose–response curve for toxicity and, consequently, narrow therapeutic windows. Capecitabine (Xeloda ...

GEMSTONE-303 is the first trial demonstrating a statistically significant survival benefit for addition of an anti-PD-L1 antibody to standard chemotherapy for advanced gastric and gastroesophageal ...

Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab ...